Dr. Soni Srivastav, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2005 Technology Pkwy, Suite 440, Mechanicsburg, PA 17050 Phone: 717-791-2540 Fax: 717-791-2549 |
Pramod K Tripathi, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2005 Technology Pkwy Ste 440, Mechanicsburg, PA 17050 Phone: 717-791-2540 Fax: 717-791-2549 |
Marianna Antonopoulou, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2005 Technology Pkwy, Suite 440, Mechanicsburg, PA 17050 Phone: 717-791-2540 Fax: 717-791-2549 |
News Archive
DiagnoCure Inc. (TSX: CUR) announced that Gen-Probe, Inc. (NASDAQ: GPRO), its partner for the development and commercialization of the PCA3 prostate cancer test, has confirmed today the beginning of a U.S. clinical study intended to secure U.S. regulatory approval of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.
Adults who include at least 150 minutes of physical activity in their routines each week live longer than those who don't, finds a new study in the American Journal of Preventive Medicine.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDA's review to be completed in the first half of 2013.
An act recently signed by President Obama will make it easier to provide epinephrine to children with severe food allergies in schools, even without a prescription. Physicians at Nationwide Children's Hospital hope the act will encourage the remaining 20 states to pass legislation, incentivizing and, in some cases, requiring that schools to have this medication available for all students since up to 6 percent of children in the United States are now diagnosed with a food allergy.
OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today the opening of its new clinical and research laboratory in Irvine, California. This state-of-the-art facility will serve as the central headquarters for operations, research, and molecular clinical lab testing.
› Verified 7 days ago